Barr changes at top
This article was originally published in The Tan Sheet
Executive Summary
Bruce Downey remains chairman and CEO of Barr Pharmaceuticals, but sheds the president and chief operating officer posts he picked up when Paul Bisaro resigned to take over at Watson in August 2007, the Montvale, N.J.-based firm says March 28. VP-Global Quality and Regulatory Affairs Christine Mundkur moves up to CEO of Barr Laboratories, the company's global generics business, which manufactures and markets the Plan B (levonorgestrel) emergency contraceptive. Answering to Mundkur, Michael Bogda becomes president and COO and Timothy Sawyer becomes executive VP-global generic sales and marketing. G. Frederick Wilkinson is named CEO of Barr's proprietary products business Duramed, and will also be responsible for Barr's global business development, including generic, proprietary and biologics activities. Barr Pharmaceuticals CFO Bill McKee has new responsibilities for coordinating global tax planning and creating cost efficiencies, according to the firm's release...
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.